Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
Related Articles
MRD Negativity & PFS Benefits in Transplant-Eligible NDMM : Oncology Times
An abstract is unavailable.
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma
This randomized clinical trial evaluates the combination of veliparib and temozolomide in treating glioblastoma.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure?
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Frontiers | Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
1 The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China 2 China-New Zealand Joint Laboratory on Biomedicine and Health, Key Laboratory of Immune Response and…
Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…